DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Miralax (Polyethylene Glycol 3350 Powder) - Published Studies


Miralax Related Published Studies

Well-designed clinical trials related to Miralax (Polyethylene Glycol 3350)

A randomised, double-blind study of polyethylene glycol 4000 and lactulose in the treatment of constipation in children. [2014]

Reduced cathartic bowel preparation for CT colonography: prospective comparison of 2-L polyethylene glycol and magnesium citrate. [2011.10]

Effect of bowel preparation with polyethylene glycol on quality of capsule endoscopy. [2011.06]

MiraLAX is not as effective as GoLytely in bowel cleansing before screening colonoscopies. [2011.04]

Low-volume bowel preparation is inferior to standard 4 1 polyethylene glycol. [2011.03]

Comparison of the effectiveness of polyethylene glycol 4000 without electrolytes and magnesium hydroxide in the treatment of chronic functional constipation in children. [2011.01]

Randomised clinical trial: MiraLAX vs. Golytely - a controlled study of efficacy and patient tolerability in bowel preparation for colonoscopy. [2011.01]

The effects of polyethylene glycosylated creatine supplementation on muscular strength and power. [2010.12]

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. [2010.12]

Morning-only one-gallon polyethylene glycol improves bowel cleansing for afternoon colonoscopies: a randomized endoscopist-blinded prospective study. [2010.11]

Clinical trial: 2-L polyethylene glycol-based lavage solutions for colonoscopy preparation - a randomized, single-blind study of two formulations. [2010.09]

Efficacy of morning-only compared with split-dose polyethylene glycol electrolyte solution for afternoon colonoscopy: a randomized controlled single-blind study. [2010.09]

A randomized single-blind trial of standard diet versus fiber-free diet with polyethylene glycol electrolyte solution for colonoscopy preparation. [2010.08]

Effective bowel cleansing before colonoscopy: a randomized study of split-dosage versus non-split dosage regimens of high-volume versus low-volume polyethylene glycol solutions. [2010.08]

Efficacy and tolerability of split-dose magnesium citrate: low-volume (2 liters) polyethylene glycol vs. single- or split-dose polyethylene glycol bowel preparation for morning colonoscopy. [2010.06]

[Effect of combination pretreatment of polyethylene glycol solution and magnesium hydroxide for colonoscopy] [2010.04]

Bowel preparation: comparing metabolic and electrolyte changes when using sodium phosphate/polyethylene glycol. [2010]

A Randomized, Double-Blind, Placebo-Controlled Trial of Polyethylene Glycol Effects on Fasting and Postprandial Rectal Sensitivity and Symptoms in Hypersensitive Constipation-Predominant Irritable Bowel Syndrome. [2009.07.03]

Differences in taste between two polyethylene glycol preparations. [2007.12]

Polyethylene glycol 3350 plus electrolytes for chronic constipation in children: a double blind, placebo controlled, crossover study. [2007.11]

A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. [2007.07]

A Randomized, Multicenter, Placebo-Controlled Trial of Polyethylene Glycol Laxative for Chronic Treatment of Chronic Constipation. [2007.03.31]

An open-label study of chronic polyethylene glycol laxative use in chronic constipation. [2007.03.15]

A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. [2006.08]

Small doses of the unabsorbable substance polyethylene glycol 3350 accelerate oro-caecal transit, but slow gastric emptying in healthy subjects. [2005.02]

[Colonic lavage prior to colonoscopy: comparable outcomes of two polyethylene-glycol preparations and a sodium-phosphate solution] [2004.01.24]

Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation. [2003.01]

Overnight efficacy of polyethylene glycol laxative. [2002.07]

Comparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation in children. [2002.05]

Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK. [2002]

New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. [2001.05]

A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. [2000.02]

Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. [1999.02]

Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. [1997.10]

Well-designed clinical trials possibly related to Miralax (Polyethylene Glycol 3350)

Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis. [2015]

The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. [2014]

Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. [2014]

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). [2014]

Hydrogel sealant versus sutures to prevent fluid egress after cataract surgery. [2014]

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. [2014]

The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. [2014]

Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial. [2014]

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. [2014]

Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. [2014]

A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. [2014]

Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure. [2013]

Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. [2013]

Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. [2012]

Clinical benefits of a new multipurpose disinfecting solution in silicone hydrogel and soft contact lens users. [2012]

A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology. [2012]

A study of the clinical activity of a gel combining monocaprin and doxycycline: a novel treatment for herpes labialis. [2012]

Oil-in-water emulsion adjuvant with influenza vaccine in young children. [2011.10.13]

A randomized trial comparing 2 doses of polidocanol sclerotherapy for hydrocele or spermatocele. [2011.10]

Response-guided telaprevir combination treatment for hepatitis C virus infection. [2011.09.15]

Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. [2011.09]

Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. [2011.09]

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. [2011.08.17]

Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C. [2011.08.15]

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. [2011.08.15]

Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. [2011.08]

Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. [2011.08]

TEM interfacial characterization of an experimental self-adhesive filling material bonded to enamel/dentin. [2011.08]

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. [2011.08]

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. [2011.08]

RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. [2011.08]

Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials. [2011.07]

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. [2011.07]

High-dose pegylated interferon-alpha and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). [2011.07]

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. [2011.07]

Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. [2011.07]

Telaprevir for retreatment of HCV infection. [2011.06.23]

Telaprevir for previously untreated chronic hepatitis C virus infection. [2011.06.23]

Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. [2011.06.15]

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. [2011.06.01]

Twice-weekly pegylated interferon-alpha-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. [2011.06.01]

Wear of dental sealing materials using the replication technique. [2011.06]

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. [2011.06]

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. [2011.06]

Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. [2011.06]

Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. [2011.06]

Eighteen-month clinical and radiographic evaluation of two root canal-filling materials in primary teeth with pulp necrosis secondary to trauma. [2011.06]

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. [2011.06]

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. [2011.06]

Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma. [2011.06]

An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. [2011.06]

A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. [2011.06]

Hydrogel-coated coils versus bare platinum coils for the endovascular treatment of intracranial aneurysms (HELPS): a randomised controlled trial. [2011.05.14]

Microleakage and marginal gap of adhesive cements for noble alloy full cast crowns. [2011.05]

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. [2011.05]

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. [2011.05]

Evaluation of MP4OX for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study. [2011.05]

Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. [2011.05]

Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. [2011.05]

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. [2011.05]

A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. [2011.04.12]

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. [2011.04.09]

Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. [2011.04]

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. [2011.04]

Achieving quality in colonoscopy: bowel preparation timing and colon cleanliness. [2011.04]

A double-blind, randomized, multicenter study of MP4OX for treatment of perioperative hypotension in patients undergoing primary hip arthroplasty under spinal anesthesia. [2011.04]

Monomer elution from nanohybrid and ormocer-based composites cured with different light sources. [2011.04]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017